Akebia Therapeutics AKBA
NASDAQ AKBA
$0.57 +0.03 (+5.89%)
At close: Nov 11, 2026 · 4:00 PM EST

Akebia Therapeutics (AKBA) Short-Term Debt repayments (2019)

Updated

Akebia Therapeutics (AKBA) recorded Short-Term Debt repayments of $32 million in FY2023, down 3.0% from $33 million in FY2022.

Analysis

Akebia Therapeutics (AKBA) Short-Term Debt repayments (2019) Analysis & Trends

  • Annual Short-Term Debt repayments has a four-year compound annual growth rate of 20.9% (FY2019 to FY2023).
  • The FY2023 figure is the lowest annual Short-Term Debt repayments since FY2019.
  • Per Business Quant data, AKBA's Short-Term Debt repayments was $33 million in FY2022 and $15 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 6.63 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Akebia Therapeutics 149.86 Mn -512.48 Mn 30.54 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 15.00 Mn
API Access

Akebia Therapeutics Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=AKBA&period=max&api_key=YOUR_API_KEY